A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past three months, 24 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), with a majority being somewhat bullish. The average 12-month price target has increased by 3.71% to $1194.29. Analysts have adjusted their ratings and price targets, reflecting their response to recent developments. Regeneron has shown strong financial performance with a notable net margin and ROE, despite lagging revenue growth compared to peers.
October 04, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received a majority of somewhat bullish ratings from analysts, with an increased average price target of $1194.29. The company's strong financial performance is highlighted by a high net margin and ROE, although its revenue growth lags behind industry peers.
The majority of analysts are somewhat bullish on Regeneron, with a notable increase in the average price target. This suggests positive sentiment and potential upward movement in the stock price. The company's strong financial metrics, such as net margin and ROE, further support this outlook, although the lag in revenue growth compared to peers may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100